Abstract
In the present invention, IgG1 Fc variants were engineered and examined for affinity to the Fc receptor and for antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and antibody-dependent cell-mediated phagocytosis effector functions. In vivo function was also examined. Several variants exhibited enhanced effector function, and optimal Fc variants were selected. These variants can be used for engineering of therapeutic antibodies with the goal of achieving improved and optimal biological activities related to Fc effector functions.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call